("AMS" or the "Group")
Notice of Preliminary ResultsWinsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the world-leading specialist in tissue-healing technologies, will announce its preliminary results for the twelve months ended 31 December 2022 on Wednesday 15 March 2023.
A briefing for analysts will be held at 10am GMT on the day of the results. For further information, please contact AMS@consilium-comms.com .
- End -
For further information, please contact:
|
Advanced Medical Solutions Group plc |
Tel: +44 (0) 1606 545508 |
|
Chris Meredith, Chief Executive Officer Eddie Johnson, Chief Financial Officer Michael King, Investor Relations |
|
|
Consilium Strategic Communications |
Tel: +44 (0) 20 3709 5700 |
|
Matthew Neal / Lucy Featherstone |
|
|
Investec Bank PLC (NOMAD & Broker) |
Tel: +44 (0) 20 7597 5970 |
|
Gary Clarence/ David Anderson |
|
|
HSBC Bank PLC (Broker) |
Tel: +44 (0) 20 7991 8888 |
|
Sam McLennan / Joe Weaving / Stephanie Cornish |
About Advanced Medical Solutions Group plc
AMS is a world-leading independent developer and manufacturer of innovative tissue-healing technology, focused on quality outcomes for patients and value for payers. AMS has a wide range of surgical products including tissue adhesives, sutures, haemostats, internal fixation devices and internal sealants, which it markets under its brands LiquiBand®, RESORBA®, LiquiBandFix8® and Seal-G®. AMS also supplies wound care dressings such as silver alginates, alginates and foams through its ActivHeal® brand as well as under white label. Since 2019, the Group has made four acquisitions: Sealantis, an Israeli medical device company with a patent-protected sealant technology platform; Biomatlante, an established French developer and manufacturer of innovative surgical biomaterial technologies, Raleigh, a UK leading coater and converter of materials predominately for woundcare and bio-diagnostics products and AFS Medical, an Austrian a specialist surgical business with a focus on minimally invasive procedures.
AMS's products, manufactured in the UK, Germany, France, the Netherlands, the Czech Republic and Israel, are sold globally via a network of multinational or regional partners and distributors, as well as via AMS's own direct sales forces in the UK, Germany, Austria, the Czech Republic and Russia. The Group has R&D innovation hubs in the UK, Germany, France and Israel. Established in 1991, the Group has more than 700 employees. For more information, please see www.admedsol.com .